Archives des Latest news - OSE Immuno Together

Shareholder note dated June 20, 2025, informing about our action to contest the extension until September 30, 2025, for holding the General Meeting.

In order to explain the reasons for the 10 draft resolutions which we have requested to be included on the agenda Dear Shareholders, As co-founders and former directors of OSE…

Read all

https://ose-immuno-ensemble.com/wp-content/uploads/2025/06/OSE-Pharma-Loria-Costantini-Peyroles-e1445893203257-1.jpg 1536 1024 OSE Immuno Together OSE Immuno Together https://ose-immuno-ensemble.com/wp-content/uploads/2025/06/OSE-Pharma-Loria-Costantini-Peyroles-e1445893203257-1.jpg 18 June 2025 13 August 2025

Latest news

Letter to shareholders ahead of OSE Immunotherapeutics SA’s June 25, 2025 Combined General Meeting, setting out the reasons for our 10 draft resolutions.

Dear OSE Immunotherapeutics Shareholders, As co-founders and former directors of OSE Immunotherapeutics, we intimately understand the company’s innovations, their commercial potential, and the paths to success. We remain major shareholders…

Read all

https://ose-immuno-ensemble.com/wp-content/uploads/2025/08/page-banner-bg.jpg 2560 904 OSE Immuno Together OSE Immuno Together https://ose-immuno-ensemble.com/wp-content/uploads/2025/08/page-banner-bg.jpg 18 June 2025 20 August 2025

Latest news

Publication by biotech financial analyst Lionel Labourdette, Biomed Impact, dated June 6, 2025.

Lionel Labourdette, PhD Inflexion de la stratégie, biomarqueur prometteur, différend avec des actionnaires historiques : difficile d'y voir clair à court terme. Nous avons décidé de pendre un peu de…

Read all

Latest news

Publication by biotech financial analyst Lionel Labourdette, Biomed Impact, dated May 7, 2025.

Lionel Labourdette, PhD Données de la phase de maintenance : des signes positifs mais encore beaucoup de chemin à parcourir Ose Immuno a présenté il y a 2 jours à…

Read all